EA202091876A1 - Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака - Google Patents

Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака

Info

Publication number
EA202091876A1
EA202091876A1 EA202091876A EA202091876A EA202091876A1 EA 202091876 A1 EA202091876 A1 EA 202091876A1 EA 202091876 A EA202091876 A EA 202091876A EA 202091876 A EA202091876 A EA 202091876A EA 202091876 A1 EA202091876 A1 EA 202091876A1
Authority
EA
Eurasian Patent Office
Prior art keywords
psma
radiotherapy
cancer
polyaminocarboxylates
targeted radio
Prior art date
Application number
EA202091876A
Other languages
English (en)
Inventor
Мартин Г. Помпер
Ронни К. Миз
Вивек Кумар
Сенджита Рэй
Майкл Залутски
Ганесан Ваидьянатан
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Дьюк Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити, Дьюк Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of EA202091876A1 publication Critical patent/EA202091876A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Описаны низкомолекулярные радиогалогенированные ингибиторы PSMA и их комплексы металлов и их применение в радиовизуализации и радиотерапии для лечения связанных с PSMA заболеваний, включая рак предстательной железы. Также описана комбинация низкомолекулярных радиогалогенированных ингибиторов PSMA с конкурирующим PSMA лигандом для снижения накопления радиогалогенированного ингибитора PSMA вне мишени.
EA202091876A 2018-02-06 2019-02-06 Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака EA202091876A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626993P 2018-02-06 2018-02-06
PCT/US2019/016821 WO2019157037A1 (en) 2018-02-06 2019-02-06 Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Publications (1)

Publication Number Publication Date
EA202091876A1 true EA202091876A1 (ru) 2020-12-10

Family

ID=67549121

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091876A EA202091876A1 (ru) 2018-02-06 2019-02-06 Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака

Country Status (12)

Country Link
US (1) US11813340B2 (ru)
EP (1) EP3749653A4 (ru)
JP (1) JP2021513542A (ru)
KR (1) KR20200141439A (ru)
CN (1) CN112020497A (ru)
AU (1) AU2019217838C1 (ru)
BR (1) BR112020016040A2 (ru)
CA (1) CA3090495A1 (ru)
EA (1) EA202091876A1 (ru)
IL (1) IL276528A (ru)
MX (1) MX2020008247A (ru)
WO (1) WO2019157037A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096526A (zh) * 2019-07-02 2022-02-25 诺华股份有限公司 前列腺特异性膜抗原（psma）配体及其用途
US20230226227A1 (en) * 2019-07-02 2023-07-20 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
EP3919082A1 (en) 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
EP4171661A1 (en) * 2020-06-29 2023-05-03 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
CN111909105B (zh) * 2020-07-22 2021-09-28 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其金属标记物及制法和应用
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
CN113372285A (zh) * 2021-05-28 2021-09-10 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1472541T1 (sl) 2002-01-10 2010-12-31 Univ Johns Hopkins Prikazovalni agensi in postopek prikazovanja naaladase ali psma
PL3699162T3 (pl) 2006-11-08 2022-10-31 Molecular Insight Pharmaceuticals, Inc. Heterodimery kwasu glutaminowego
EP3466928A1 (en) 2007-06-26 2019-04-10 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
EP3656403B1 (en) 2007-08-17 2022-05-11 Purdue Research Foundation Preparation process of psma binding ligand-linker conjugates
EP4089074A1 (en) * 2008-08-01 2022-11-16 The Johns Hopkins University Psma-binding agents and uses thereof
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
BRPI0922779A8 (pt) * 2008-12-05 2018-06-19 Molecular Insight Pharm Inc complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma
WO2010108125A2 (en) 2009-03-19 2010-09-23 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2011106639A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8926944B2 (en) * 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
ES2941937T3 (es) 2011-11-30 2023-05-26 Univ Johns Hopkins Compuesto dirigido a PSMA y sus usos
US9760886B2 (en) * 2013-05-10 2017-09-12 Visa International Service Association Device provisioning using partial personalization scripts
GEP20237496B (en) * 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6749249B2 (ja) 2014-05-06 2020-09-02 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
WO2017070482A2 (en) * 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
EP3925952B1 (en) * 2016-03-22 2023-11-29 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
CA3090495A1 (en) 2019-08-15
US20210220493A1 (en) 2021-07-22
AU2019217838A1 (en) 2020-09-24
EP3749653A4 (en) 2021-12-15
AU2019217838C1 (en) 2024-05-02
AU2019217838B2 (en) 2024-02-01
WO2019157037A1 (en) 2019-08-15
US11813340B2 (en) 2023-11-14
IL276528A (en) 2020-09-30
JP2021513542A (ja) 2021-05-27
CN112020497A (zh) 2020-12-01
EP3749653A1 (en) 2020-12-16
BR112020016040A2 (pt) 2020-12-08
KR20200141439A (ko) 2020-12-18
MX2020008247A (es) 2021-02-26

Similar Documents

Publication Publication Date Title
EA202091876A1 (ru) Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
PH12020551908A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
CL2009000133A1 (es) Compuestos derivados de ftalazinona, inhibidores de la actividad parp; composicion farmaceutica; uso en el tratamiento de enfermedades vasculares, shock septico, lesion isquemica, neurotoxicidad, shock hemorragico, como auxiliar en la terapia del cancer de mama, de ovario, de pancreas, entre otras.
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
TN2018000383A1 (en) Pde9 inhibitors for treatment of peripheral diseases.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
TN2017000507A1 (en) Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
EA201790323A1 (ru) Ингибиторы протеинкиназы c и способы их применения
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
MX336761B (es) Compuestos para el tratamiento de cancer.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
EA201591706A1 (ru) Солевые формы (s)-хинуклидин-3-ил-(2-(2-(4-фторфенил)тиазол-4-ил)пропан-2-ил)карбамата
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида